Core Laboratories Q2 revenue falls as geopolitical disruptions weigh
CLB•Outlook
- Core Laboratories projects Q3 2026 revenue between $128.5 mln and $135.5 mln
- Company expects Q3 2026 EPS of $0.12 to $0.20
- Core Laboratories says ongoing conflicts likely to affect client operations in Q3 2026
Overview
- Oilfield services provider's Q2 revenue fell 4% yr/yr and rose 2% sequentially
- Adjusted EPS for Q2 rose 85% sequentially but declined 42% yr/yr
- Company repurchased 214,712 shares for $2.7 mln during the quarter
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | $124.6 mln | $125.1 mln (2 Analysts) | |
| Q2 EPS | $0.13 |
Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst coverage
- The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
- The average consensus recommendation for the business support services peer group is "buy"
- Wall Street's median 12-month price target for Core Laboratories Inc is $13.50, about 36.8% above its July 29 closing price of $9.87
